

## Viracta Therapeutics to Present at the 2020 BIO CEO & Investor Conference

*PR Newswire, San Diego, February 4, 2020* - Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, announced today that Dan Chevallard, Chief Financial Officer of Viracta, will present a company overview at the 2020 BIO CEO and Investor Conference on Tuesday, February 11, 2020 at 2:30 pm ET in New York, NY.

### **About Viracta Therapeutics, Inc.**

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with valganciclovir as an oral combination therapy in a Phase 2 clinical trial for Epstein-Barr virus-associated lymphomas. Viracta is pursuing application of this Kick and Kill treatment approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, and other viral-related cancers. For additional information please visit [www.viracta.com](http://www.viracta.com).

### **Media Contact:**

Amy Conrad  
Juniper Point  
[amy@juniper-point.com](mailto:amy@juniper-point.com)  
858-366-3243

### **Investor Contact:**

Sam Martin  
Argot Partners  
[sam@argotpartners.com](mailto:sam@argotpartners.com)  
212-600-1902

---

<https://viracta.investorroom.com/2020-02-04-Viracta-Therapeutics-to-Present-at-the-2020-BIO-CEO-Investor-Conference>